Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease.
Saved in:
| Title: | Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease. |
|---|---|
| Authors: | Mendes D; Pfizer Ltd, Tadworth, UK., Averin A; Policy Analysis Inc. (PAI), Chestnut Hill, MA, USA., Atwood M; Policy Analysis Inc. (PAI), Chestnut Hill, MA, USA., Sato R; Pfizer Inc, Collegeville, PA, USA., Vyse A; Pfizer Ltd, Tadworth, UK., Campling J; Pfizer Ltd, Tadworth, UK., Weycker D; Policy Analysis Inc. (PAI), Chestnut Hill, MA, USA., Slack M; School of Medicine & Dentistry, Griffith University, Gold Coast Campus, 4222, Australia., Ellsbury G; Pfizer Ltd, Tadworth, UK., Mugwagwa T; Pfizer Ltd, Tadworth, UK. |
| Source: | Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2022 Dec; Vol. 22 (8), pp. 1285-1295. Date of Electronic Publication: 2022 Nov 03. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101132257 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8379 (Electronic) Linking ISSN: 14737167 NLM ISO Abbreviation: Expert Rev Pharmacoecon Outcomes Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1744-8379 |
|---|---|
| DOI: | 10.1080/14737167.2022.2134120 |
